In a report released yesterday, Charles Rhyee from TD Cowen maintained a Buy rating on CVS Health (CVS – Research Report), with a price target of $80.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Charles Rhyee has given his Buy rating due to a combination of factors that indicate potential growth for CVS Health. Rhyee’s analysis suggests that the management’s targets for 2025 are conservative, particularly in terms of the ongoing medical cost trends and the growth in Pharmacy Services. The estimated adjusted earnings per share (EPS) for 2025 is $5.97, aligning with management’s guidance and indicating room for potential upside.
Rhyee also notes the strong performance in the Health Care Benefits (HCB) segment and its alignment with management’s expectations. The Health Services segment shows a positive outlook with adjusted operating income projected to surpass management’s guidance. These factors, along with the stable guidance for the Pharmacy Services and consistent performance across various segments, underpin Rhyee’s optimistic outlook and Buy rating for CVS Health.
In another report released on February 14, Leerink Partners also upgraded the stock to a Buy with a $75.00 price target.